Kymera Therapeutics, Inc.

Hello, and welcome to the Chimera Therapeutics second quarter 2023 quarterly results call. I'd now like to turn the call over to Bruce Jacobs.

Mr. Jacobs, please go ahead.

Good morning, everyone, and welcome to the Chimera Therapeutics Quarterly Conference Call. I'm Bruce Jacobs, Chief Financial Officer at Chimera, and I'll be joined today by Neville Minalti, Founder, President, and CEO, Jared Gold, our Chief Medical Officer, and I'm also excited to welcome Justine Konigsberg, Chimera's new Head of Investor Relations, to her first Chimera Quarterly Call. After our prepared remarks, we'll open the call to your questions, as we always do, and Before we get started, I'd like to remind everyone that some of the comments that management may make on this call include forward-looking statements as outlined in the press release. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those set forth in Chimera's most recent filings with the SEC and any other future filings that the company may make with the SEC. Your caution not to place any undue reliance on those forward-looking statements and Chimera disclaims any obligations to update such statements except as required by law. With that said, I'll now hand the call over to Nello.